Please Wait
Applying Filters...
menu
    • menu
    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-24

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-17

    Virtual Booth

    Contact Supplier

    Menu

    Relacorilant

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA Files Corcept's NDA for Relacorilant in Hypercortisolism
    FDA Files Corcept's NDA for Relacorilant in Hypercortisolism

    03 Mar 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250303227690/en

    BUSINESSWIRE
    03 Mar 2025
    Share Share
    Corcept Submits NDA for Relacorilant in Hypercortisolism
    Corcept Submits NDA for Relacorilant in Hypercortisolism

    30 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241230947567/en

    BUSINESSWIRE
    30 Dec 2024
    Share Share
    Corcept’s Relacorilant Ph 3 Shows Cardiometabolic Improvements
    Corcept’s Relacorilant Ph 3 Shows Cardiometabolic Improvements

    16 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241216461773/en

    BUSINESSWIRE
    16 Dec 2024
    Share Share
    Corcept's GRACE Relacorilant Hypercortisolism Phase 3 Data Presented
    Corcept's GRACE Relacorilant Hypercortisolism Phase 3 Data Presented

    03 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/03/2892174/0/en/Corcept-Therapeutics-Announces-Presentations-of-Results-of-Pivotal-Phase-3-GRACE-Trial-Evaluating-Relacorilant-in-Patients-with-Hypercortisolism-Cushing-s-Syndrome.html

    GLOBENEWSWIRE
    03 Jun 2024
    Share Share
    Corcept: GRACE Trial Met Primary Endpoint In Cushing's Syndrome
    Corcept: GRACE Trial Met Primary Endpoint In Cushing's Syndrome

    28 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/28/2888977/0/en/Corcept-Announces-Primary-Endpoint-Met-in-Pivotal-Phase-3-GRACE-Trial-of-Relacorilant-in-Patients-With-Hypercortisolism-Cushing-s-Syndrome.html

    GLOBENEWSWIRE
    28 May 2024
    Share Share
    Corcept Completes Enrollment in Pivotal Ph 3 Trial of Relacorilant
    Corcept Completes Enrollment in Pivotal Ph 3 Trial of Relacorilant

    08 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/08/2859131/0/en/Corcept-Completes-Enrollment-in-Pivotal-Phase-3-Rosella-Trial-of-Relacorilant-in-Patients-With-Platinum-Resistant-Ovarian-Cancer.html

    GLOBENEWSWIRE
    08 Apr 2024
    Share Share